Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Completes Enrollment in Anti-GBM","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Receives Positive CHMP Opinion for IdefirixTM (imlifidase) for Kidney Transplant in EU","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"$407.5 million","upfrontCash":"$10.0 million","newsHeadline":"Hansa Biopharma Inks Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Conditional Approval for Hansa's Idefirix[tm] (imlifidase) in Highly Sensitized Kidney Transplant Patients in the European Union","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Provides Updated Guidance on Its Clinical Programs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharm Announces Positive High-Level Data from Investigator-Initiated Phase 2 Trial with Imlifidase to Treat Anti-GBM Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hansa Biopharma Enters Preclinical Research Collaboration with Argenx","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma to Initiate Phase 3 Study of Imlifidase to Treat Anti-Glomerular Basement Membrane (anti-GBM) dIsease After Successful Pre-Ind Meeting With U.S. FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Enrolls First Patient in U.S. Randomized, Controlled Pivotal Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE recommends use of Hansa Biopharma's Idefirix\u00ae (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix\u00ae in Highly Sensitized Kidney Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma And Partner Sarepta Therapeutics Plan To Initiate A Clinical Study With Imlifidase As A Pre-treatment To Sarepta\u2019s SRP-9001 Gene Therapy In DMD In 2023","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Announces Positive Reimbursement Decision in Italy For Idefirix\u00ae (imlifidase) As Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix\u00ae (imlifidase) in the Czech Republic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Announces First Patient Dosed with Imlifidase in A Global Pivotal Phase 3 Trial in Anti-Glomerular Basement Membrane (anti-GBM) Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix (imlifidase) in Belgium as Desensitization Treatment for Highly Sensitized Patients in kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 study in ANCA-associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imlifidase met Primary Endpoint in 16-HMedIdes-12 Phase 2 Trial in Patients with AMR Following Kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imlifidase Demonstrated Positive Safety, Tolerability, and Early Efficacy Outcomes in 15-HMedIdeS-09 Phase 2 Trial in Guillain-Barr\u00e9 Syndrome (GBS)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Hansa Biopharma

    Menu

    Hansa Biopharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Imlifidase met Primary Endpoint in 16-HMedIdes-12 Phase 2 Trial in Patients with AMR Following Kidney Transplantation

              Details:

              Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated for the treatment of highly sensitized kidney transplant patients.

              Lead Product(s): Imlifidase

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Imlifidase Demonstrated Positive Safety, Tolerability, and Early Efficacy Outcomes in 15-HMedIdeS-09 Phase 2 Trial in Guillain-Barré Syndrome (GBS)

              Details:

              Idefirix (Imlifidase), IgG degrader enzyme in combination with Immunoglobulin antibodies. It is being evaluating in the Phase II clinical trial studies for the treatment of Guillain-Barre Syndrome.

              Lead Product(s): Imlifidase,Immunoglobulin

              Therapeutic Area: Rare Diseases and Disorders Product Name: Idefirix

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

              Details:

              Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated for the treatment of highly sensitized kidney transplant patients.

              Lead Product(s): Imlifidase

              Therapeutic Area: Immunology Product Name: Idefirix

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

              Details:

              HNSA-5487 is a next-generation IgG-cleaving enzyme, which is investigated for the treatment of IgG-driven autoimmune disease and experience flares, transplantation where repeat dosing would be beneficial, gene therapy and oncology.

              Lead Product(s): HNSA-5487

              Therapeutic Area: Immunology Product Name: HNSA-5487

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 study in ANCA-associated Vasculitis

              Details:

              Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated in phase 2 study in anti-neutrophil cytoplasmic antibody ("ANCA")-associated vasculitis.

              Lead Product(s): Imlifidase

              Therapeutic Area: Immunology Product Name: Idefirix

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix (imlifidase) in Belgium as Desensitization Treatment for Highly Sensitized Patients in kidney Transpl...

              Details:

              Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. Idefirix® is conditionally authorized by the European Commission (EC) for the desensitization treatment of highly sensitized adult kidney transplant patients.

              Lead Product(s): Imlifidase

              Therapeutic Area: Immunology Product Name: Idefirix

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hansa Announces First Patient Dosed with Imlifidase in A Global Pivotal Phase 3 Trial in Anti-Glomerular Basement Membrane (anti-GBM) Disease

              Details:

              Idefirix® (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the treatment of anti-glomerular basement membrane (anti-GBM) disease.

              Lead Product(s): Imlifidase,Cyclophosphamide

              Therapeutic Area: Immunology Product Name: Idefirix

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix® (imlifidase) in the Czech Republic

              Details:

              Idefirix (Imlifidase), an enzyme derived from bacterium streptococcus pyogenes, specifically target and cleave all classes of IgG antibodies. Imlifidase is a promising new strategy for desensitization of transplant patients with donor-specific anti-HLA antibodies.

              Lead Product(s): Imlifidase

              Therapeutic Area: Immunology Product Name: Idefirix

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hansa Biopharma Announces Positive Reimbursement Decision in Italy For Idefirix® (imlifidase) As Desensitization Treatment for Highly Sensitized Patients in Kidney Transpl...

              Details:

              Idefirix® having Imlifidase, company’s first-in-class treatment, for the desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor.

              Lead Product(s): Imlifidase

              Therapeutic Area: Immunology Product Name: Idefirix

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hansa Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hansa Biopharma And Partner Sarepta Therapeutics Plan To Initiate A Clinical Study With Imlifidase As A Pre-treatment To Sarepta’s SRP-9001 Gene Therapy In DMD In 2023

              Details:

              SRP-9001 (delandistrogene moxeparvovec), is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.

              Lead Product(s): Delandistrogene Moxeparvovec,Imlifidase

              Therapeutic Area: Genetic Disease Product Name: SRP-9001

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Sarepta Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY